---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-120154"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2024-11-01T23:59:59+00:00"
generated_at: "2026-05-30T06:57:46.636916+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Iterum issues $20M promissory note to Pfizer at 8% interest for deferred milestone payment

## Summary
- FDA approved ORLYNVAH (sulopenem) on Oct 25 for uncomplicated UTIs in adult women.
- $20M regulatory milestone payment triggered under 2015 Pfizer license agreement.
- Company elected to defer payment for 2 years (until Oct 25, 2026) via promissory note.
- Note bears 8% annual interest compounded daily; prepayable without penalty.
- Upon change of control during deferral, Pfizer may accelerate full payment plus interest.

## SEC filing metadata
- accession: 0000950170-24-120154
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2024-11-01T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017024120154/0000950170-24-120154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017024120154/itrm-20241028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-120154
- JSON: https://secwatch.observer/filing/0000950170-24-120154.json
- Plain text: https://secwatch.observer/filing/0000950170-24-120154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.